

HIV Coinfection

TABLE 156: HIV COINFECTION GENOTYPE 1 TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8	PR48	1.86 (1.01 to 3.01)	33.75 (0.48 to 56.91)
B44 PR48		1.79 (1.11 to 2.65)	31.22 (4.26 to 50.01)
SOF24 + RBV24		2.08 (1.39 to 3.36)	42.12 (18.37 to 62.52)
SOF12 + LDV12		2.46 (1.72 to 3.78)	56.76 (35.76 to 71.78)
B44 PR48	T12 PR48 q8	0.97 (0.54 to 1.75)	-2.21 (-37.16 to 33.93)
SOF24 + RBV24		1.12 (0.75 to 2.03)	8.67 (-21.18 to 44.27)
SOF12 + LDV12		1.31 (0.98 to 2.31)	22.71 (-2.02 to 55.09)
SOF24 + RBV24	B44 PR48	1.15 (0.80 to 2.07)	10.85 (-16.48 to 44.64)
SOF12 + LDV12		1.35 (1.03 to 2.33)	24.98 (2.11 to 55.37)
SOF12 + LDV12	SOF24 + RBV24	1.17 (0.92 to 1.56)	14.10 (-7.13 to 34.95)
Random effect model	Residual deviance	10.15 vs. 12 data points	
	Deviance information criteria	56.046	
Fixed effect model	Residual deviance	10.02 vs. 12 data points	
	Deviance information criteria	55.736	

B = boceprevir; BEC = beclabuvir; Crl = credible interval; LDV = ledipasvir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.